DHN198
Phase 1- Indications
- Solid tumors
Company intelligence / Profile preview
Duhn Therapeutics
Dijon, Bourgogne-Franche-Comté, Franceduhn-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Duhn Therapeutics is advancing DHN198, a lipid-based small molecule cancer immunotherapy, into clinical development for solid tumors linked to chronic non-resolved immunosuppressive inflammation. The company’s approach aims to both inhibit tumor-driven immune suppression and activate anti-tumor immunity. Clinical results have not yet been published.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeLipid-based drugCancer immunotherapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
OM Pharma SA – global exclusive license for DHN198University of Bourgogne – translational research collaborationGeorges François Leclerc Cancer Treatment Center – clinical collaborationLaboratory of Immunology and Cancer Immunotherapy (LIIC) – R&D partnership
Beyond the preview
Go deeper on Duhn Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Duhn Therapeutics.